Last 12 quarters of trend data · Healthcare · Biotechnology
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | -3.52 | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| P/S Ratio | 33.02 | 112.10 | 67.01 | 38.80 | 25.66 | 15.35 | 23.22 | — | — | — | — | — | — |
| — | +630.5% | +188.5% | — | — | — | — | — | — | — | — | — | — | |
| P/B Ratio | 1.04 | 2.93 | 1.96 | 1.76 | 0.76 | 0.50 | 0.43 | 0.64 | 2.27 | — | — | — | — |
| — | +483.6% | +355.3% | +173.4% | -66.5% | — | — | — | — | — | — | — | — | |
| P/FCF | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 100.0% | 100.0% | 97.7% | 100.0% | 100.0% | 100.0% | 100.0% | — | — | — | — | — | — |
| — | 0.0% | -2.3% | — | — | — | — | — | — | — | — | — | — | |
| Operating Margin | -1031.5% | -1196.8% | -915.4% | -923.4% | -1126.6% | -1027.0% | -1133.4% | — | — | — | — | — | — |
| — | -16.5% | +19.2% | — | — | — | — | — | — | — | — | — | — | |
| Net Margin | -896.1% | -1064.7% | -802.8% | -842.9% | -982.0% | -894.0% | -891.0% | — | — | — | — | — | — |
| — | -19.1% | +9.9% | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -27.1% | -6.9% | -6.8% | -9.4% | -7.0% | -7.1% | -4.1% | -6.6% | -40.1% | — | — | — | — |
| — | +2.4% | -68.2% | -42.3% | +82.4% | — | — | — | — | — | — | — | — | |
| ROA | -24.7% | -6.6% | -6.4% | -8.6% | -6.4% | -6.5% | -3.7% | -6.1% | -9.3% | -7.9% | -12.6% | -80.8% | — |
| — | -1.4% | -74.5% | -42.4% | +31.1% | +18.0% | +70.9% | +92.5% | — | — | — | — | — | |
| ROIC | -210.2% | -9.9% | -16.5% | -27.0% | -22.8% | -24.9% | -56.7% | — | — | — | — | — | — |
| — | +60.3% | +70.8% | — | — | — | — | — | — | — | — | — | — |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
| Metric | TTM | Q2 '26 | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q1 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.01 | 0.01 | 0.02 | 0.03 | 0.03 | 0.03 | 0.03 | 0.03 | — | — | — | — |
| — | -74.5% | -67.7% | -24.1% | -21.0% | — | — | — | — | — | — | — | — | |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — | — | — |
| — | — | — | — | — | — | — | — | — | — | — | — | — | |
| Current Ratio | 14.24 | 17.19 | 24.76 | 14.24 | 11.87 | 13.21 | 13.68 | 12.86 | 17.63 | 12.61 | 11.81 | 0.44 | — |
| — | +30.1% | +80.9% | +10.8% | -32.7% | +4.8% | +15.9% | +2855.3% | — | — | — | — | — | |
| Quick Ratio | 14.24 | 17.19 | 24.76 | 14.24 | 11.87 | 13.21 | 13.68 | 12.86 | 17.63 | 12.61 | 11.81 | 0.44 | — |
| — | +30.1% | +80.9% | +10.8% | -32.7% | +4.8% | +15.9% | +2855.3% | — | — | — | — | — | |
| Interest Coverage | -114.65 | -26096.00 | -569.59 | -280.99 | -134.38 | -106.28 | -49.70 | -65.24 | -59.33 | -29.66 | -9.68 | -7.19 | -14.51 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 12 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying BIOA stock.
BioAge Labs Inc.'s current P/E is -3.5x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
BioAge Labs Inc.'s current operating margin is -1031.5%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking BioAge Labs Inc.'s business trajectory between earnings reports.